Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes by Tayal, B. et al.
Listen to this manuscript’s
audio summary by
JACC Editor-in-Chief
Dr. Valentin Fuster.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 7 1 , N O . 1 2 , 2 0 1 8
ª 2 0 1 8 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N
P U B L I S H E D B Y E L S E V I E RCardiac Resynchronization Therapy in
Patients With Heart Failure and
Narrow QRS Complexes
Bhupendar Tayal, MD, PHD,a John Gorcsan III, MD,b Jeroen J. Bax, MD, PHD,c Niels Risum, MD, PHD,d
Niels Thue Olsen, MD, PHD,e Jagmeet P. Singh, MD,f William T. Abraham, MD, PHD,g Jeffrey S. Borer, MD,h
Kenneth Dickstein, MD, PHD,i Daniel Gras, MD,j Henry Krum, MB, BS, PHD,k Josep Brugada, MD,l
Michele Robertson, BSC,m Ian Ford, PHD,m Johannes Holzmeister, MD,n Frank Ruschitzka, MD,n
Peter Sogaard, MD, DMSCaABSTRACTISS
Fro
cLe
De
Bo
Re
Ins
Un
Re
Cli
Kin
spo
Me
Bo
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outcome after cardiac resynchronization therapy (CRT) in patients with heart failure (HF) with wide QRS. However, its
signiﬁcance in patients with narrow QRS treated with CRT is unknown.
OBJECTIVES The aim of the current study was to investigate the association of mechanical activation delay by CCA
with study outcome in patients with HF enrolled in the EchoCRT trial.
METHODS Baseline CCA could be performed from tissue Doppler imaging in the apical views in 807 of 809 (99.7%)
enrolled patients, and 6-month follow-up could be performed in 610 of 635 (96%) patients with available
echocardiograms. Patients with a pre-speciﬁed maximal activation delay $35 ms were considered to have signiﬁcant
delay. The study outcome was HF hospitalization or death.
RESULTS Of 807 patients, 375 (46%) did not have delayed mechanical activation at baseline by CCA. Patients without
delayed mechanical activation who were randomized to CRT-On compared with CRT-Off had an increased risk of poor
outcome (hazard ratio: 1.70; 95% conﬁdence interval: 1.13 to 2.55; p ¼ 0.01) with a signiﬁcant interaction term
(p ¼ 0.04) between delayed mechanical activation and device randomization for the endpoint. Among patients with
paired baseline and follow-up data with no events before 6-month follow-up (n ¼ 541), new-onset delayed mechanical
activation in the CRT-On group showed a signiﬁcant increase in unfavorable events (hazard ratio: 3.73; 95% conﬁdence
interval: 1.15 to 12.14; p ¼ 0.03).
CONCLUSIONS In the EchoCRT population, absence of delayed mechanical activation by CCA was signiﬁcantly
associated with poor outcomes, possibly due to the onset of new delayed mechanical activation with CRT pacing.
(Echocardiography Guided Cardiac Resynchronization Therapy [EchoCRT] Trial; NCT00683696)
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1326S everal studies in the past havedemonstrated that the assessment ofmechanical dyssynchrony by echocar-
diography can supplement current electrocar-
diographic criteria (wide QRS $120 ms) in
selecting cardiac resynchronization therapy
(CRT) candidates, leading to an overall reduc-
tion in the nonresponders rate (1–3). However,conventional methods of identifying dyssynchrony
based on segmental time-to-peak measurements have
failed when applied in randomized trials for selecting
patients for CRT with narrow QRS (<130 ms) (4,5).SEE PAGE 1334The largest CRT trial conducted on patients with
narrow QRS (<130 ms)—EchoCRT (Echocardiography
Guided Cardiac Resynchronization Therapy)—demon-
strated that patients with heart failure (HF) with nar-
row QRS (<130 ms) do not respond to CRT despite the
presence of baseline mechanical dyssynchrony by
time-to-peak methods, by either tissue Doppler longi-
tudinal velocity or speckle tracking radial strain (4).
In fact, an increased incidence of mortality was
observed in patients randomized to CRT-On compared
with the control group, and the trial was stopped due
to futility without achieving its complete target
population. Another trial—RethinQ (Resynchroniza-
tion Therapy in Narrow QRS)—which was performed
before EchoCRT, with a similar design where me-
chanical dyssynchrony was 1 of the selection criteria,
also showed no beneﬁt of CRT in patients with HF with
narrow QRS (5).
More recently, it was shown that peak-to-peak
measures of mechanical dyssynchrony may be
inﬂuenced by contractile heterogeneity or scar not
responsive to CRT (6). Patterns of myocardial
mechanics that have been shown to reﬂect electricaloston Scientiﬁc, Sorin Group, Medtronic, and St. Jude Medical; p
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better identify a true substrate for CRT response (6–8).
These newer methods seem superior to the conven-
tional time-to-peak methods (7,9). Among these,
one approach is the assessment of mechanical acti-
vation delay by cross correlation analysis (CCA) using
tissue Doppler imaging (TDI) (7,10). The presence of a
delayed mechanical activation by CCA in patients
with wide QRS is associated with improved prognosis
as well as response after CRT (7,10,11). However, its
signiﬁcance is unknown in patients with HF with
narrow QRS (<130 ms) treated with CRT. Accordingly,
the objective of the current study was to assess the
association of delayed mechanical activation using
the CCA method both at baseline and follow-up after
randomization to clinical outcomes in patients
enrolled in the EchoCRT trial.
METHODS
STUDY POPULATION. The current study was a pre-
speciﬁed substudy of the EchoCRT trial. All patients
included in the EchoCRT trial had left ventricular (LV)
ejection fraction #35%, QRS duration of #130 ms,
severe symptomatic HF with New York Heart Asso-
ciation functional class III to IV symptoms, LV end-
diastolic diameter $55 mm, and echocardiographic
evidence of mechanical dyssynchrony by time-to-
peak methods. In this study, dyssynchrony was
identiﬁed by the presence of TDI-based opposing wall
delay of $80 ms in the apical 4- or 3-chamber view,
and radial strain delay $130 ms between the septum
and the posterior walls in the LV midsegment short-
axis view. All patients included in the trial were
older than 18 years and provided informed consent. It
was a multicenter randomized trial, in which patients
were enrolled from 2008 to 2013 in 112 centers from 22ersonal fees from CardioInsight Inc.; has served as a
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FIGURE 1 Examples Comparing Dyssynchrony by Time-to-Peak and Activation Delay by CCA
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Two examples from the trial showing dyssynchrony by time-to-peak ($80 ms) opposing wall delay using tissue Doppler imaging. However, only the patient in the
top row has a signiﬁcant activation delay ($35 ms) on cross correlation analysis (CCA). The patient in the bottom row has nearly no activation delay (6 ms). This can be
visually appreciated when we compare the acceleration curves of the septum and lateral walls (third column) of the 2 panels.
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1327different countries. Patients with bradycardia pacing
or atrial ﬁbrillation within the past few months were
excluded. The main study results along with a
detailed study protocol have been published (4). All
study patients received a CRT device with deﬁbril-
lator capacity (CRT-D) (Biotronik Lumax, Berlin,
Germany) and were randomized 1:1 to CRT-On or -Off
after a successful implantation of the device. For the
current substudy, 807 (99.7%) of 809 patients were
included with the baseline data and 610 (96%) of 635
patients were included with paired data at both
baseline and 6-month follow-up.
CROSS CORRELATION ANALYSIS. All echocardio-
grams were performed using a single-vendor ultra-
sound system (GE Vivid 7 or E9, Horton, Norway). To
reduce variability, the ofﬂine TDI-based analysis was
performed on a single GE EchoPAC system (version BT
11) by a single observer (B.T.) blinded to the patient
data. CCA has been illustrated in detail in our previous
publications (Figure 1) (7,10,11). Brieﬂy, regions of
interest (7  15 mm) were placed on the base segmentsof the opposing walls in all 3 apical views, and the
resulting velocity datawere imported on an automated
Excel sheet (Microsoft, Redmond, Washington) with
a pre-written algorithm to perform CCA analysis.
Subsequently, velocity data were converted to accel-
eration data by using time differentiation. A baseline
correlation coefﬁcient was calculated between the ac-
celeration curves from 2 opposing walls during systole
in each of the 3 apical views without time-shift. These
acceleration curves were then time-shifted against
each other frame-by-frame to a maximum of 15 frames
in both directions to calculate a correlation coefﬁcient
again. The time-shift resulting in the maximum
correlation between the opposing walls was termed as
maximum activation-delay (AD-max). Patients were
classiﬁed as having signiﬁcant activation delay if the
AD-max was $35 ms in any of the 3 apical views based
on our previous work (7,10). Systole was identiﬁed by
calculating the aortic valve opening and closure
timings from a pulse Doppler signal in the APLAX view.
Activation delay by CCA was measured at both
TABLE 1 Baseline Characteristics
CRT-Off With No AD CRT-On With No AD CRT-Off With AD CRT-On With AD
Total Statistics Total Statistics Total Statistics Total Statistics
Age, yrs 181 57.4  11.72 194 57.0  13.07 223 59.2  13.12 209 58.1  12.77
Male 181 127 (70.17) 194 145 (74.74) 223 163 (73.09) 209 149 (71.29)
QRS width, ms 180 104.0  12.04 192 106.1  12.43 221 106.7  12.00 205 105.9  13.65
Walking distance, m 175 317.5  118.93 192 330.7  123.38 219 326.9  124.84 204 325.7  114.31
Quality-of-life score 181 55.2  23.63 194 51.5  25.07 221 47.5  24.14 208 51.3  23.67
NYHA functional class 181 194 223 209
I 1 (0.55) 2 (1.03) 2 (0.90) 0 (0.00)
II 5 (2.76) 4 (2.06) 7 (3.14) 3 (1.44)
III 170 (94) 184 (95) 204 (91) 200 (96)
IV 5 (2.76) 4 (2.06) 10 (4.48) 6 (2.87)
BNP, pg/ml 99 244 (89–613) 109 242 (40–493) 94 290 (126–600) 91 224 (115–564)
NT-proBNP, pg/ml 77 1,071 (462–2,203) 74 1,121 (414–2,444) 122 923 (529–1,999) 110 1,378 (556–2,675)
Sitting SBP, mm Hg 181 118  16 194 118  22 223 122  21 209 117  18
Sitting DBP, mm Hg 181 73  11 194 73  13 223 73  13 209 73  12
BMI, kg/m2 181 30  7 194 31  15 223 32  16 209 31  7
Ischemic cardiomyopathy 180 93 (52) 194 99 (51) 223 120 (54) 209 119 (57)
MI >3 months ago 181 71 (39) 194 69 (36) 223 83 (37) 209 98 (47)
PCI >3 months ago 181 56 (31) 194 74 (38) 223 74 (33) 209 98 (47)
CABG >3 months ago 181 35 (19) 194 35 (18) 223 39 (17) 209 42 (20)
Hypertension 178 119 (67) 194 124 (64) 223 151 (68) 205 137 (67)
Congenital heart disease 175 3 (1.7) 192 3 (1.6) 220 7 (3.2) 206 3 (1.5)
Prior ischemic stroke or TIA 180 28 (16) 193 19 (10) 221 19 (9) 207 30 (14)
Diabetes 181 69 (38) 193 77 (40) 222 84 (38) 208 89 (43)
Chronic lung disease 180 33 (18) 191 30 (16) 220 45 (20) 209 39 (19)
Chronic kidney disease 180 17 (9) 192 30 (16) 220 25 (11) 209 36 (17)
LVEF biplane, % 181 27.4  5.3 194 27.4  5.5 223 26.7  5.6 209 26.7  5.8
LV end-diastolic diameter, mm 181 66  7 194 67  7 223 67  8 209 67  8
ACE inhibitor or ARB 181 177 (98) 194 185 (95) 223 206 (92) 209 197 (94)
Aldosterone antagonist 181 105 (58) 194 118 (61) 223 132 (59) 209 128 (61)
Beta-blocker 181 178 (98) 194 183 (94) 223 216 (97) 209 203 (97)
Diuretic agent 181 160 (88) 194 160 (82) 223 191 (86) 209 185 (88)
MR grade 180 192 221 206
None/trace 69 (38) 64 (33) 77 (35) 69 (34)
Mild 65 (36) 80 (42) 89 (40) 83 (40)
Moderate 25 (14) 31 (16) 34 (15) 33 (16)
Moderate/severe 14 (8) 11 (6) 12 (5) 14 (7)
Severe 7 (4) 6 (3) 9 (4) 7 (3)
LVESV, ml 180 134  47 194 140  49 223 142  54 207 142  49
LVEDV, ml 180 183  57 194 191  58 223 192  65 207 190  55
TDI, ms 181 97  39 194 98  34 223 105  34 208 104  31
Radial strain delay, ms 173 218  109 181 213  100 202 223  102 191 223  99
Values are n, mean  SD, n (%), or median (interquartile range).
ACE ¼ angiotensin-converting enzyme; AD ¼ activation delay; ARB ¼ angiotensin II receptor blocker; BMI ¼ body mass index; BNP ¼ brain natriuretic peptide;
CABG ¼ coronary artery bypass surgery; CRT ¼ cardiac resynchronization therapy; DBP ¼ diastolic blood pressure; LV ¼ left ventricular; LVEDV ¼ left ventricular end-diastolic
volume; LVEF¼ left ventricular ejection fraction; LVESV¼ left ventricular end-systolic volume; MI ¼myocardial infarction; MR ¼mitral regurgitation; NT-proBNP ¼ N-terminal
pro-b natriuretic peptide; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; SBP ¼ systolic blood pressure; TDI ¼ tissue Doppler imaging;
TIA ¼ transient ischemic attack.
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1328baseline and 6 months. For the analysis of patients
with paired CCA data, patients were divided into the
following 4 groups based on the presence or absence of
mechanical activation at baseline and follow-up:
1. No activation delay: no activation delay at both
baseline and at follow-up.2. Improved activation delay: activation delay at
baseline but not at follow-up.
3. Persistent activation delay: activation delay at
baseline and at follow-up.
4. New activation delay: no activation delay at base-
line but activation delay at follow-up.
FIGURE 2 Baseline Activation Delay and Outcome
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1329STUDY OUTCOME. The outcome variable of this
study was the primary endpoint of all-cause death or
ﬁrst HF hospitalization within a period of 3.5 years.
STATISTICAL ANALYSIS. All statistical analyses were
performed by an independent Statistical Centre at the
Robertson Centre for Biostatistics, University of
Glasgow. Baseline characteristics were compared
with the use of analysis of variance tests or chi-square
tests for continuous and categorical variables,
respectively. Hazard ratios (HRs) for CRT-On and -Off
with 95% conﬁdence intervals (CIs) were calculated
with the Cox proportional hazards models for treat-
ment effect and country of recruitment as a covariate.
The interaction between delay subgroup and ran-
domized treatment group was tested in a Cox model
that included delay subgroup and treatment main
effect and interaction terms. Time-to-event curves
were estimated using the Kaplan-Meier method.
RESULTS
The 807 patients with baseline CCA analysis data
were equally distributed, with 404 (50.1%) patients in
the CRT-Off group and 403 (49.9%) in the CRT-On
group. Of these 807 patients, time-to-peak dyssyn-
chrony data was available in 806 patients: 420 (52%)
patients had dyssynchrony by both radial strain andTDI opposing wall delay, 201 (25%) had dyssynchrony
by lone TDI, and the remaining 185 (23%) patients had
dyssynchrony by lone radial strain. A signiﬁcant
mechanical activation delay by CCA was observed in
223 (55%) of the CRT-Off patients and in 209 (52%)
CRT-On patients. The baseline characteristics of
the patients in the CRT-Off and -On groups based
on activation delay are summarized in Table 1.
No signiﬁcant differences in baseline characteristics
were observed between the groups.
ASSOCIATION OF BASELINE MECHANICAL ACTIVATION
DELAY BY CCA WITH LONG-TERM OUTCOME. The trial
was stopped due to futility by the independent data
and monitoring board. The median follow-up period
was 1.15 years (interquartile range: 0.48 to 2.05
years). HF hospitalizations and all-cause death were
observed in 216 (27%) patients by the time the trial
was stopped. Separately, there were 187 HF hospi-
talizations and 29 deaths in the follow-up interval of
3.5 years. On dividing the patients into 4 groups, it
was observed that patients with no mechanical acti-
vation delay by CCA in the CRT-On group experienced
the highest number of events (32%) (Figure 2). Among
patients with no mechanical activation delay,
patients randomized to CRT-On group had an
increased risk of an unfavorable outcome compared
with those with CRT-Off: HR: 1.7 (95% CI: 1.13 to 2.55;
p ¼ 0.01) (Figure 3). However, among patients with
presence of activation delay, no signiﬁcant difference
was observed for events among the 2 CRT randomiza-
tion groups (HR: 0.96 [95% CI: 0.66 to 1.40]; p ¼ 0.84).
Importantly, there was a signiﬁcant interaction term
between activation delay by CCA and randomization to
CRT device for the outcome events (p ¼ 0.04).
CHANGES IN MECHANICAL ACTIVATION DELAY
ASSOCIATED WITH OUTCOME. At 6-month follow-
up, echocardiographic data for the CCA was avail-
able in 610 (96%) of 635 patients with follow-up
echocardiograms. After excluding patients who were
hospitalized for HF before the 6-month follow-up
analysis, a ﬁnal number of 541 patients were avail-
able for follow-up analysis. Among these, 274 (51%)
were from CRT-Off and 267 (49%) were from the
CRT-On group. The distribution of the 4 groups based
on mechanical activation delay at baseline and
follow-up among patients with CRT-Off and -On was
similar: no activation delay (31% vs. 30%), improved
activation delay (27% vs. 31%), persistent activation
delay (27% vs. 23%), and onset of new activation
delay (15% vs. 16%).
A total of 102 patients experienced either HF hos-
pitalization or death from 6 months until complete
follow-up time, excluding events that occurred in the
FIGURE 3 Baseline Activation Delay and Time to Events
100
80
60
40
Pa
tie
nt
s W
ith
 H
ea
rt
 F
ai
lu
re
 H
os
pi
ta
liz
at
io
n
or
 D
ea
th
 A
ft
er
 C
RT
20
0
0
181
194
223
209
139
139
162
157
109
104
126
118
76
70
89
84
57
52
62
50
35
32
36
32
24
21
20
20
7
10
8
9
CRT = OFF, No Activation Delay:
CRT = ON, No Activation Delay:
CRT = OFF, Activation Delay:
CRT = ON, Activation Delay:
0.5 1 1.5
Interaction P value = 0.04
Years Since Randomization
2
CRT =  OFF, No Activation Delay <35ms
CRT =  OFF, Activation Delay ≥35ms CRT =  ON, Activation Delay ≥35ms
CRT =  ON, No Activation Delay <35ms
2.5 3 3.5
Kaplan-Meier curve showing the time to events for the 4 patient groups based on the presence or absence of activation delay at baseline and
cardiac resynchronization therapy (CRT) device randomization.
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1330ﬁrst 6 months. The event rate was signiﬁcantly higher
among patients with a new mechanical activation
delay observed on the 6-month echocardiogram in
the CRT-On group compared with the CRT-Off group
(30% vs. 12%; HR: 3.73; 95% CI: 1.15 to 12.14; p ¼ 0.03)
(Central Illustration). No signiﬁcant difference was
observed for the outcome events between the other 3
groups based on randomization.
DISCUSSION
This pre-speciﬁed substudy of the EchoCRT trial of
patients with HF with narrow QRS width shows that
the absence of mechanical activation delay by CCA at
baseline and new-onset activation delay observed
in follow-up in patients treated with CRT was
signiﬁcantly associated with poor clinical outcomes
(Central Illustration). These results support the notion
that delayed activation by CCA is measuring adifferent mechanical phenomenon than time-to-peak
dyssynchrony. These observations may provide new
insight into the interpretation of the EchoCRT trial
and the mechanistic workings of CRT in general.
The EchoCRT trial used the best documented
methods for dyssynchrony for selection of patients at
the time of study design, that is, both longitudinal
TDI velocity and 2-dimensional speckle tracking
radial strain time-to-peak assessment. In patients
with HF with wide QRS, these methods have
demonstrated additive prognostic value (1,2,12).
Moreover, single-center studies using these methods
have shown improved HF symptoms and LV reverse
remodeling in patients with narrow QRS HF with
echocardiographic dyssynchrony treated by a CRT
device, comparable to patients with wide QRS (13,14).
Meanwhile, questions have been raised regarding the
speciﬁcity of these methods (4–6,10). Time-to-peak
measurements alone do not provide any information
CENTRAL ILLUSTRATION Cross Correlation Analysis by Tissue Doppler Imaging and
Outcome in Patients With Narrow QRS Treated With CRT
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Tayal, B. et al. J Am Coll Cardiol. 2018;71(12):1325–33.
(A) Increased hospitalization due to heart failure and mortality in patients with no activation delay at baseline and implanted with
cardiac resynchronization therapy (CRT) with a signiﬁcant interaction between device randomization and activation delay for the endpoints.
(B) Patients with new activation delay after CRT compared with those with no CRT had poor outcome, indicating the role of device-induced
activation delay in the poor prognosis.
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1332on the nature of the wall deformation, such as
whether differences are due to scarring or activation
timing differences (6). Although time-to-peak differ-
ences due to abnormalities in the myocardial tissue
are demonstrated to have prognostic signiﬁcance in
various types of cardiomyopathies (15,16), it is not
correctable by CRT speciﬁcally in the absence of
concomitant electrical dyssynchrony (4,5). The re-
sults of the current analysis strengthen the view that
peak-to-peak methods are relatively nonspeciﬁc for
detecting true dyssynchrony responsive to CRT, as
only one-half of the patients included in the EchoCRT
trial had signiﬁcant mechanical activation delay by
CCA. Mechanical activation delay by CCA may be less
susceptible to differences in mechanical motion pat-
terns not caused by delayed activation (7,10). CCA
analysis in patients with wide QRS complex under-
going CRT has proven beneﬁcial in identifying re-
sponders with both wide and intermediate QRS
durations, and has evaluated resynchronization efﬁ-
cacy to obtain maximum CRT beneﬁt (7,10,11).
Unlike the CCA method, which is more of a
quantitative approach, other qualitative methods for
the assessment of dyssynchrony, such as identiﬁca-
tion of typical contraction pattern (9) and apical
rocking (8), are proposed to identify the true pa-
tients with left bundle branch block (LBBB) with
activation delay. Both of these methods have shown
excellent additional value in identifying potential
responders to CRT in patients with LBBB, which is
principally due to exclusion of patients who are
misdiagnosed as LBBB by electrocardiography. The
unique contraction pattern of the opposing walls,
described by Risum et al. (9), is speciﬁc to patients
with true LBBB and would be physiologically
implausible in other kinds of cardiomyopathy. On
the other hand, dyssynchrony by CCA quantiﬁes the
activation delay between 2 opposing walls rather
than relying on a speciﬁc contraction pattern, and
thus could be applicable in patients other than
LBBB also. It has not only demonstrated to be
superior to TDI time-to-peak in patients with
wide QRS in predicting survival after CRT, but has
also shown promising results in the intermediate
QRS (120 to 149 ms) patients (7).
It seems, however, that even when selecting pa-
tients with the stricter CCA criteria for mechanical
activation delay, there is no convincing positive effect
of CRT in patients with HF with narrow QRS. One
possible explanation could be that mechanical acti-
vation delay in the setting of narrow QRS needs not
represent a substrate amenable to CRT. The follow-up
CCA analysis agrees with this interpretation, as CRTwas inefﬁcient in correcting mechanical activation
delay in a large group of patients. Even though CCA is
less susceptible to other motion differences between
LV walls, it is likely that mechanical activation can be
delayed for other reasons than delays in electrical
activation, such as differences in electro-mechanical
coupling. It should also be considered that the study
sample size was reduced by premature termination of
the trial, and there are relatively wide conﬁdence
limits to these subgroup estimates of treatment effect.
The strongest signal of our analysis is the
suggestion of a harmful effect of CRT isolated to
patients with no activation delay at baseline by
CCA. This is an important ﬁnding given the higher
mortality observed in the CRT-On group in the
EchoCRT trial. Follow-up evaluation conﬁrmed that
particularly patients without activation delay ran-
domized to CRT-On who developed new activation
delay had a signiﬁcantly worse outcome, with an
almost 4-fold increased risk of adverse events.
Similar observations have been made regarding new
or worsened activation delay during CRT in patients
with a wide QRS (11,17–19). This ﬁnding of potential
harm from CRT in patients without baseline
mechanical activation delay also ﬁts well with a
previous study of CCA in patients with intermediate
to wide QRS HF treated with CRT, where lack of
baseline activation delay was associated with a poor
long-term outcome (7).
There are several interesting perspectives in the
present analysis. First, when considering HF
patients with narrow QRS #130 ms, it seems the
prevalence of potential responders to CRT is quite
low, and will be hard to identify, even with
advanced methods such as CCA. Second, in patients
with HF with intermediate QRS 130 to 149 ms, the
prevalence of potential responders is probably
higher, and as the effect of CRT overall in this group
is less well established, there could be a role for
methods such as CCA to select patients for CRT in
future trials. Third, in patients with HF with inter-
mediate or broad QRS >150 ms, CCA seems an
attractive method for detecting patients that are
potentially harmed by CRT. This sets the stage for
potential trials in the future of deferral of CRT
in patients without mechanical activation delay,
or trials of turning off CRT in patients where
new-onset mechanical activation delay cannot be
corrected by optimization.
STUDY LIMITATIONS. The current study is a post hoc
study. Although it was a pre-speciﬁed substudy that
was approved before the EchoCRT trial commenced,
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: This study
demonstrates the limitation of the time-to-peak based dyssyn-
chrony measures which are applied in the routine clinical practice.
Nearly, one-half of patients did not have signiﬁcant activation
delay by CCA when applied on patients having dyssynchrony by
time-to-peak based methods. CRT was particularly fatal to
patients with narrow QRS who lacked activation delay at baseline
by CCA due to the risk of pacemaker induced new activation delay.
TRANSLATIONAL OUTLOOK: Randomized studies are
needed to assess the utility of CCA for selection of patients with
intermediate QRS duration (120 to 140 ms) for CRT.
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1333the method applied in the study was not a part of the
patient selection process for the trial. Another limi-
tation of the study was the lack of 6-month follow-up
echocardiograms in many patients: 610 patients had
6-month follow-up echocardiograms for CCA, result-
ing in a loss of about 24% of patients for the follow-up
analysis. This was mostly due to the premature
closure of the study.
CONCLUSIONS
The effect of CRT in patients with HF with narrow
QRS (#130 ms) in terms of HF hospitalization and
death depends on LV mechanical activation delay
determined by echocardiographic CCA. CRT specif-
ically resulted in poor outcomes in patients with HF
with narrow QRS and no activation delay by CCA at
baseline, which is most probably caused by the
pacing-induced development of new activation delay.
This study provides new mechanistic insights into the
effects of CRT pacing in patients with HF, which is of
clinical signiﬁcance.ADDRESS FOR CORRESPONDENCE: Dr. Bhupendar
Tayal, Aalborg University Hospital, Hobrovej 18-22,
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